Indexat a

Llicència i ús

Citacions

Altmetrics

Grant support

Dr Cepas-Guillen is recipient of a grant from Fundacion Alfonso Martin Escudero (Madrid, Spain). Dr Rodes-Cabau holds the Research Chair Fondation Famille Jacques Lariviere for the Development of Structural Heart Disease Interventions (Laval University).

Impacte en els Objectius de Desenvolupament Sostenible (ODS)

Anàlisi d'autories institucional

Compartir

Validation of the Valve Academic Research Consortium High Bleeding Risk Definition in Patients Undergoing TAVR

Publicat a:Circulation-Cardiovascular Interventions. 18 (1): e014800- - 2025-01-01 18(1), DOI: 10.1161/CIRCINTERVENTIONS.124.014800

Autors: Avvedimento, Marisa; Cepas-Guillen, Pedro; Ternacle, Julien; Urena, Marina; Alperi, Alberto; Cheema, Asim; Veiga-Fernandez, Gabriela; Nombela-Franco, Luis; Vilalta, Victoria; Esposito, Giovanni; Campelo-Parada, Francisco; Indolfi, Ciro; del Trigo, Maria; Munoz-Garcia, Antonio; Maneiro, Nicolas; Asmarats, Lluis; Regueiro, Ander; del Val, David; Serra, Vicenc; Auffret, Vincent; Modine, Thomas; Bonnet, Guillaume; Mesnier, Jules; Suc, Gaspard; Avanzas, Pablo; Rezaei, Effat; Fradejas-Sastre, Victor; Tirado-Conte, Gabriela; Fernandez-Nofrerias, Eduard; Franzone, Anna; Guitteny, Thibaut; Sorrentino, Sabato; Francisco Oteo, Juan; Nuche, Jorge; Gutierrez-Alonso, Lola; Flores-Umanzor, Eduardo; Alfonso, Fernando; Monastyrski, Andrea; Nolf, Maxime; Cote, Melanie; Mehran, Roxana; Morice, Marie-Claude; Capodanno, Davide; Garot, Philippe; Rodes-Cabau, Josep

Afiliacions

Resum

BACKGROUND:The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) has recently introduced a consensus document that outlines risk factors to identify high bleeding risk in patients undergoing transcatheter aortic valve replacement. The objective of the present study was to evaluate the prevalence and predictive value of the VARC-HBR definition in a contemporary, large-scale transcatheter aortic valve replacement population.METHODS:Multicenter study including 10 449 patients undergoing transcatheter aortic valve replacement. Based on consensus, 21 clinical and laboratory criteria were identified and classified as major or minor. Patients were stratified as at low, moderate, high, and very high bleeding risk according to the VARC-HBR definition. The primary end point was the rate of Bleeding Academic Research Consortium type 3 or 5 bleeding at 1 year, defined as the composite of periprocedural (within 30 days) or late (after 30 days) bleeding.RESULTS:Patients with at least 1 VARC-HBR criterion (n=9267, 88.7%) had a higher risk of Bleeding Academic Research Consortium 3 or 5 bleeding, proportional to the severity of risk assessment (10.8%, 16.1%, and 24.6% for moderate, high, and very-high-risk groups, respectively). However, a comparable rate of bleeding events was observed in the low-risk and moderate-risk groups. The area under receiver operating characteristic curve was 0.58. Patients with VARC-HBR criteria also exhibited a gradual increase in 1-year all-cause mortality, with an up to 2-fold increased mortality risk for high and very-high-risk groups (hazard ratio, 1.33 [95% CI, 1.04-1.70] and 1.97 [95% CI, 1.53-2.53], respectively).CONCLUSIONS:The VARC-HBR consensus offered a pragmatic approach to guide bleeding risk stratification in transcatheter aortic valve replacement. The results of the present study would support the predictive validity of the new definition and promote its application in clinical practice to minimize bleeding risk and improve patient outcomes.

Paraules clau